Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Imai H, Kijima T, Azuma K, Kishi K, Saito H, Yamaguchi T, Tanizaki J, Yoneshima Y, Fujita K, Watanabe S, Kitazono S, Fukuhara T, Hataji O, Toi Y, Mizutani H, Hamakawa Y, Maemondo M, Ohsugi T, Suzuki K, Horinouchi H, Ohe Y. Imai H, et al. Among authors: yoneshima y. Jpn J Clin Oncol. 2024 Apr 6;54(4):452-462. doi: 10.1093/jjco/hyad195. Jpn J Clin Oncol. 2024. PMID: 38271158 Free PMC article.
Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors.
Takada K, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, Wakasu S, Takamori S, Toyokawa G, Oba T, Osoegawa A, Tagawa T, Oda Y, Nakanishi Y, Mori M. Takada K, et al. Among authors: yoneshima y. J Cancer Res Clin Oncol. 2020 May;146(5):1217-1225. doi: 10.1007/s00432-020-03146-5. Epub 2020 Feb 5. J Cancer Res Clin Oncol. 2020. PMID: 32025867
Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Okamoto I, Nokihara H, Nomura S, Niho S, Sugawara S, Horinouchi H, Azuma K, Yoneshima Y, Murakami H, Hosomi Y, Atagi S, Ozaki T, Horiike A, Fujita Y, Okamoto H, Ando M, Yamamoto N, Ohe Y, Nakagawa K. Okamoto I, et al. Among authors: yoneshima y. JAMA Oncol. 2020 May 1;6(5):e196828. doi: 10.1001/jamaoncol.2019.6828. Epub 2020 May 14. JAMA Oncol. 2020. PMID: 32163097 Free PMC article. Clinical Trial.
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.
Kenmotsu H, Wakuda K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Shukuya T, Masuda K, Hayashi H, Toyozawa R, Miura S, Fujimoto D, Nakagawa K, Yamamoto N, Takahashi T. Kenmotsu H, et al. Among authors: yoneshima y. J Thorac Oncol. 2022 Sep;17(9):1098-1108. doi: 10.1016/j.jtho.2022.05.006. Epub 2022 May 27. J Thorac Oncol. 2022. PMID: 35636696 Free article. Clinical Trial.
Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer.
Ibusuki R, Yoneshima Y, Hashisako M, Matsuo N, Harada T, Tsuchiya-Kawano Y, Kishimoto J, Ota K, Shiraishi Y, Iwama E, Tanaka K, Oda Y, Okamoto I. Ibusuki R, et al. Among authors: yoneshima y. Transl Lung Cancer Res. 2022 Nov;11(11):2208-2215. doi: 10.21037/tlcr-22-393. Transl Lung Cancer Res. 2022. PMID: 36519019 Free PMC article.
Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.
Shimokawa T, Okamoto H, Machida R, Misumi Y, Hosomi Y, Yoneshima Y, Tanaka H, Okishio K, Simizu J, Goto K, Akamatsu H, Kubota K, Nakagawa K, Horinouchi H, Ando M, Kataoka T, Ohe Y. Shimokawa T, et al. Among authors: yoneshima y. Lung Cancer. 2023 Jul;181:107195. doi: 10.1016/j.lungcan.2023.107195. Epub 2023 Apr 22. Lung Cancer. 2023. PMID: 37156212 Free article. Clinical Trial.
Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE).
Haratani K, Nakamura A, Mamesaya N, Mitsuoka S, Yoneshima Y, Saito R, Tanizaki J, Fujisaka Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Sato Y, Nakano Y, Otani T, Sakai K, Tomida S, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H. Haratani K, et al. Among authors: yoneshima y. J Thorac Oncol. 2023 Oct;18(10):1334-1350. doi: 10.1016/j.jtho.2023.06.012. Epub 2023 Jun 25. J Thorac Oncol. 2023. PMID: 37364849 Free article.
75 results